ArticleFrontiers in oncology2025
Clinical value of quantitative analysis of Sonazoid-contrast enhanced ultrasound combined with shear wave elastography in discriminating and diagnosing breast tumor characteristics.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multimodal transformers predict cancer therapy response from tumor mechanics.Array (New York, N.Y.) · 2026Article
- A Dual-Transducer Approach for High-Resolution and High-Precision Shear Wave Elasticity Imaging.Sensors (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This research intends to probe the clinical value of combining Sonazoid-contrast-enhanced ultrasound (S-CEUS) quantitative analysis with shear wave elastography (SWE) for discriminating and diagnosing the nature of breast tumors. Methods: A total of 108 breast tumor patients (comprising 120 breast lesions) who were classified as category 4 breast tumor cases and underwent routine ultrasound examinations (June 2022-June 2023) were selected for this study. S-CEUS and SWE examinations were conducted on these breast lesions. The morphological characteristics of S-CEUS were assessed, including morphology (regular, irregular), boundary (clear, unclear), and internal enhancement (no enhancement, homogeneous enhancement, heterogeneous enhancement), along with dynamic enhancement features. Additionally, the maximum Young's modulus (Emax) from SWE examinations was recorded, and the results were compared to the gold standard in pathology. The diagnostic efficacy of S-CEUS quantitative analysis, SWE alone, or their combined assessment in determining the nature of breast tumors was evaluated. Results: Among the cohort of 108 patients, a total of 120 category 4 breast lesions were analyzed, revealing 68 cases (56.67%) of pathologically confirmed malignant breast tumors and 52 cases (43.33%) of benign breast tumors. Malignant breast tumors exhibited irregular morphology, unclear boundaries, heterogeneous internal enhancement, high enhancement levels, increased enhancement ranges, perfusion defects, and predominantly washout-type time-signal intensity curve patterns. These characteristics were significantly more prevalent in malignant tumors compared to benign tumors (p<0.05). Furthermore, quantitative assessment denoted that malignant breast tumors showcased higher CEUS quantitative scores than benign tumors (p<0.05). The Emax for malignant breast tumors was (91.36 ± 24.15) kPa, which was considerably higher than that for benign breast tumors [(49.86 ± 20.31) kPa] ( Conclusion: Both S-CEUS quantitative analysis and SWE are valuable tools for the evaluation of benign and malignant characteristics in breast tumors. Particularly, their combined application demonstrates superior diagnostic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.